Don Tracy, Associate Editor
Articles
Pharma Regulatory Strategies Could Shift as Vaccine Support Declines
August 22nd 2025Ron Lanton, partner, Lanton Law, explains that declining public trust and political support for vaccines could force pharmaceutical companies to rethink regulatory strategies and investment priorities in biologics and vaccine development.
What Supply Chain Leaders Need to Know About COVID Vaccine Policy Uncertainty
August 21st 2025Ron Lanton, Partner, Lanton Law, warns that shifting federal policies and ongoing lawsuits could create compliance challenges and operational risks that pharmaceutical supply chain leaders must closely monitor.
Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production
July 16th 2025Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.
Sustaining Regulatory Engagement Through Industry and Advocacy Collaboration
July 10th 2025Bruce Leuchter, CEO, Neurvati, explains how industry and advocacy groups can work together to ensure patient and caregiver perspectives continue to inform regulatory decisions—even without a formal public engagement pathway.
How Patient Advocacy Is Guiding Rare Disease Drug Development
July 1st 2025Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how patient and caregiver insights shape drug development, regulatory decisions, and payer considerations in rare diseases.
